Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-06-18

Targeting Inflammation and Neurogenesis using cannabinoids to delay the onset of Alzheimer’s disease

Objetivo

Alzheimer’s disease (AD) is the most common neurodegenerative disease and accounts for the majority of diagnosed dementia after age 60. It is estimated to currently affect between 20 and 30 million people worldwide, with 4 millions in the U.S. alone. As life expectancy increases in developed countries, the prevalence of AD, and its burden on healthcare, is very likely to increase dramatically in the next few decades. While waiting for a cure for AD as its prevalence will increase drastically over the years, a medication approach that would delay the onset of the disease would have a major impact of the disease incidence and prevalence, and thus on its burden on the economy of industrialized countries. Our main hypothesis is that excessive inflammatory processes (and its subsequent effect on protein function like MMPs and neurogenesis) are part of the early events triggering deleterious processes observed in AD later on. We do hypothesize that a diminution (but not complete inhibition) of those inflammatory processes, notably using the EC system, could benefit brain functions (neurogenesis, memory processes, APP processing to non-toxic amyloid forms…) and thus decrease the incidence of AD by delaying/reducing the appearance of hallmarks of AD. This proposal will then clarify the possible influence in vivo of chronic inflammation and its pharmacological modulation (and inflammatory-related proteases as MMPS), as well as neurogenic processes and behavior in a well-established transgenic model of AD. This study will thus provide valuable mechanistic information underlying the possible modulating role of the inflammation, MMPs and EC in the development of the AD pathology. Overall, those experiments could pave the way to a possible active treatment aiming at lowering the incidence of AD.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Convocatoria de propuestas

FP7-PEOPLE-2009-RG
Consulte otros proyectos de esta convocatoria

Régimen de financiación

MC-IRG - International Re-integration Grants (IRG)

Coordinador

UNIVERSITE D'AIX MARSEILLE
Aportación de la UE
€ 100 000,00
Dirección
BOULEVARD CHARLES LIVON 58 LE PHARO
13284 Marseille
Francia
Región
Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos

Participantes (1)